HAYWARD, CA -- (MARKET WIRE) -- 12/21/2005 -- Aradigm Corporation (NASDAQ: ARDM) today announced the completion of manufacturing of pivotal and clinical batches of its Intraject Sumatriptan product on its commercial-scale manufacturing line. With the successful transfer of technology and analytical methods to the company's Contract-Manufacturing Partners, final product release testing is currently underway and, pending partnering of the product, would be available for a pivotal bioequivalence trial in 2006.
